News + Font Resize -

Chemokine gets US patent for stem cell technique
Vancouver, BC | Saturday, July 5, 2008, 08:00 Hrs  [IST]

Chemokine Therapeutics Corp., a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, announced that it has been granted US Patent No. 7,378,098.

Patent No. 7,378,098 entitled "CXC Chemokine Receptor 4 Agonist Peptides" is related to treatment of patients in need of bone marrow or stem cell transplantation. This patent is based on evidence that treatment with SDF-1 chemokine analog prevents reduction of normal bone marrow stem cells and restores white blood cells, which reduce susceptibility to infections in cancer patients following chemotherapy treatment.

"This patent strengthens the foundation for our work with our drug candidate CTCE-0214, for hematogical support; mobilization of stem cells and white blood cells into circulation, which is currently in phase I development" said Dr. Donald Wong, vice president, drug development.

Post Your Comment

 

Enquiry Form